Metabolomics-Based Clinical Efficacy of Compound Shenlu Granule, a Chinese Patent Medicine, in the Supportive Management of Aplastic Anemia Patients: A Randomized Controlled Pilot Trial

<div>OPLS-DA scores and model parameters before and after treatment in group B. (a) Score scatter plot and (b) the model parameters (R2X = 0.22, R2Y = 0.87, and Q2 = 0.49).</div>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: Metabolomics-Based Clinical Efficacy of Compound Shenlu Granule, a Chinese Patent Medicine, in the Supportive Management of Aplastic Anemia Patients: A Randomized Controlled Pilot Trial 

Figure 3 | Metabolomics-Based Clinical Efficacy of Compound Shenlu Granule, a Chinese Patent Medicine, in the Supportive Management of Aplastic Anemia Patients: A Randomized Controlled Pilot Trial 